Article Text

Download PDFPDF
The effect of posterior vitreous detachment on aflibercept response in diabetic macular oedema
  1. Cemal Özsaygili,
  2. Bekir Küçük,
  3. Yener Yildirim
  1. Kayseri City Training and Research Hospital, Kayseri, Turkey
  1. Correspondence to Cemal Özsaygili, Ophthalmology Department, Kayseri City Training and Research Hospital, Kocasinan, Kayseri, Turkey;cemalozsaygili{at}


Purpose To investigate the effect of posterior vitreous detachment (PVD) on aflibercept response in treatment-naïve diabetic macular oedema (DME).

Design A retrospective cohort study.

Methods One hundred and fifty eyes of 150 treatment-naïve patients with DME were enrolled. The patients were divided into three groups according to their PVD status: group 1 (no PVD during injections), group 2 (PVD during injections) and group 3 (PVD already present initially). Three consecutive aflibercept injections at intervals of 1 month were applied to all patients. The efficacy of the aflibercept treatment on DME was assessed by comparing changes in central retinal thickness (CRT) and best-corrected visual acuity (BCVA) values after three loading dose injections.

Results After three consecutive injections, the mean reduction of CRT in groups 1, 2 and 3 were −199.6±106.9, −224.9±124.1 and −210.7±126.3, respectively. The decrease in CRT was significant in all groups (p<0.001 in all groups, paired-samples t-test); however, mean changes in CRT were similar among groups (all p>0.05, one-way analysis of variance (ANOVA)). The mean improvement in BCVA in groups 1, 2 and 3 was 6.6±0.9, 6.5±0.8 and 6.1±0.4 ETDRS letters, respectively. The improvement of BCVA was significant in all groups (p<0.001 in all groups, paired-samples t-test) and mean changes were similar between groups (p>0.05, one-way ANOVA). There was no significant relationship between the presence or development of PVD and the mean decrease of CRT and improvement of BCVA (for CRT r=−0.052, p=0.531 and for BCVA r=−0.078, p=0.342).

Conclusion In the present study, it was observed that the efficacy of aflibercept treatment in patients with DME did not depend on PVD status.

  • Aflibercept
  • Diabetic Macular Edema
  • Eylea
  • Posterior Vitreous Detachment

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter Dr.Cemal ÖZSAYGILI.

  • Contributors CO—corresponding author. BK—coauthor. YY—coauthor. CO, BK, YY contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript.

  • Funding No sources of support and no funding were received for this study.

  • Competing interests None declared.

  • Data sharing statement Data are available upon reasonable request.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • At a glance
    Frank Larkin